Navigation Links
InVitria Sponsors ESACT 2009 in Dublin, Ireland

InVitria, a leading supplier of performance enhancing cell culture media supplements, to sponsor the 21st Meeting of the European Society for Animal Cell Technology (ESACT) in Dublin, Ireland from June 7-10, 2009.

Fort Collins, CO June 5, 2009 / b3c newswire / – The world-renowned ESACT ‘09 gathering will serve as host to scientific experts from academia and industry brought together to find “Cellular Solutions for Clinical Challenges.” As one of the sponsors, InVitria will be sharing with attendees the powerful effects of its portfolio of cell culture media supplements developed to solve the regulatory and performance challenges facing the life science industry.

InVitria recently introduced a new product called ZAP-CHO, a performance enhancing cell culture media supplement designed to improve cell growth and antibody production in mammalian cell culture.

“ZAP-CHO improves CHO product development in chemically defined media that are completely free of animal components,” said Steve Pettit, Ph.D., Director of Cell Culture Development with InVitria.  “Previously, the performance enhancements gained with ZAP-CHO was only possible by utilizing animal components such as FBS (fetal bovine serum or fetal calf serum) in cell culture media,” said Dr. Pettit.

Additionally, ZAP-CHO speeds-up cell line development and seed train expansion and also offers cost saving benefits by reducing operating costs as well as capital investment.
Recent publications, along with customer results has validated that another of InVitria’s leading cell culture supplements, Cellastim, a recombinant human serum albumin, outperforms other forms of albumin for growth and productivity. Cellastim is a key component in stem cell media and is used to safely optimize performance in CHO and hybridoma cell lines.

“ESACT is a tremendous venue to build awareness of InVitria’s product portfolio and collaborate with leaders in cellular biology,” said Scott Deeter, InVitria President and CEO. “InVitria’s products provide a unique opportunity for the cellular products industry to advance to a higher level of safety and productivity.”

About InVitria -
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture products and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

Erik H. Vogel
Marketing Manager
Phone: 1-800-916-8311

b3c newswire

Related biology news :

1. InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO
2. InVitria Announces Launch of Recombinant Albumin for Diagnostics
3. Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center
4. WPI professor receives Fulbright Scholarship to work on tissue engineering in Ireland
5. Darwin anniversary heralds new conservation research era for Northern Ireland
6. Ireland Cancer Center researcher finds most triple-negative breast cancers express muc-1 target
7. For good or ill Ireland gains another mammal species
8. Ireland Cancer Center researchers advance stem cell gene therapy
Post Your Comments:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology: